Variant | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AF EXOME | AF GENOME | Disease | Disease Class | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
1.000 | 0.080 | 10 | 44345031 | regulatory region variant | G/A;C | snv |
|
Nervous System Diseases; Mental Disorders | 0.700 | 1.000 | 1 | 2009 | 2009 | ||||||||
|
0.925 | 0.040 | 10 | 44331285 | intergenic variant | G/A;C | snv |
|
Musculoskeletal Diseases | 0.700 | 1.000 | 1 | 2018 | 2018 | ||||||||
|
0.925 | 0.040 | 10 | 44331285 | intergenic variant | G/A;C | snv |
|
0.700 | 1.000 | 1 | 2018 | 2018 | |||||||||
|
10 | 44364170 | intergenic variant | G/A | snv | 8.4E-02 |
|
0.700 | 1.000 | 1 | 2019 | 2019 | ||||||||||
|
0.851 | 0.200 | 10 | 44378805 | intron variant | C/T | snv | 0.32 |
|
0.700 | 1.000 | 1 | 2019 | 2019 | ||||||||
|
0.925 | 0.080 | 10 | 44373979 | intron variant | A/G;T | snv |
|
Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases | 0.700 | 1.000 | 1 | 2011 | 2011 | ||||||||
|
1.000 | 10 | 44368720 | downstream gene variant | C/T | snv | 3.9E-02 |
|
0.700 | 1.000 | 1 | 2014 | 2014 | |||||||||
|
1.000 | 10 | 44368720 | downstream gene variant | C/T | snv | 3.9E-02 |
|
Nervous System Diseases | 0.700 | 1.000 | 1 | 2014 | 2014 | ||||||||
|
1.000 | 10 | 44368720 | downstream gene variant | C/T | snv | 3.9E-02 |
|
0.700 | 1.000 | 1 | 2014 | 2014 | |||||||||
|
1.000 | 10 | 44368720 | downstream gene variant | C/T | snv | 3.9E-02 |
|
0.700 | 1.000 | 1 | 2014 | 2014 | |||||||||
|
1.000 | 10 | 44368720 | downstream gene variant | C/T | snv | 3.9E-02 |
|
0.700 | 1.000 | 1 | 2014 | 2014 | |||||||||
|
10 | 44384812 | intron variant | T/C | snv | 0.26 |
|
0.700 | 1.000 | 1 | 2019 | 2019 | ||||||||||
|
0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 |
|
Neoplasms; Skin and Connective Tissue Diseases | 0.060 | 1.000 | 6 | 2009 | 2017 | |||||||
|
0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 |
|
Neoplasms; Skin and Connective Tissue Diseases | 0.060 | 1.000 | 6 | 2009 | 2017 | |||||||
|
0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 |
|
Pathological Conditions, Signs and Symptoms; Neoplasms | 0.050 | 1.000 | 5 | 2007 | 2013 | |||||||
|
0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 |
|
Neoplasms | 0.040 | 1.000 | 4 | 2011 | 2018 | |||||||
|
0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 |
|
Neoplasms | 0.030 | 1.000 | 3 | 2011 | 2018 | |||||||
|
0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 |
|
Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases | 0.030 | 0.667 | 3 | 2010 | 2017 | |||||||
|
0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 |
|
Cardiovascular Diseases | 0.020 | 0.500 | 2 | 2014 | 2015 | |||||||
|
0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 |
|
Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases | 0.020 | 1.000 | 2 | 2009 | 2018 | |||||||
|
0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 |
|
Digestive System Diseases; Neoplasms | 0.020 | 1.000 | 2 | 2007 | 2018 | |||||||
|
0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 |
|
Digestive System Diseases; Neoplasms | 0.020 | 1.000 | 2 | 2009 | 2018 | |||||||
|
0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 |
|
0.020 | 1.000 | 2 | 2007 | 2018 | ||||||||
|
0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 |
|
Neoplasms | 0.020 | 1.000 | 2 | 2009 | 2011 | |||||||
|
0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 |
|
Cardiovascular Diseases | 0.020 | 1.000 | 2 | 2014 | 2015 |